Share on LinkedInShare on LinkedIn

ARTICLE · 25 MARCH 2024

Federal Circuit Upholds PTAB Finding Of Obviousness In Pfizer vs. Sanofi

In Pfizer Inc. vs. Sanofi Pasteur Inc., the Federal Circuit upheld the Patent Trial and Appeal Board (PTAB) decision to invalidate portions of Pfizer's pneumococcal...

United StatesIntellectual Property

In Pfizer Inc. vs. Sanofi Pasteur Inc., the Federal Circuit upheld the Patent Trial and Appeal Board (PTAB) decision to invalidate portions of Pfizer's pneumococcal vaccine patent on the grounds of obviousness. My colleague's post discusses the Federal Circuit's decision to vacate and remand to the PTAB to further consider Pfizer's motions to amend with regards to proposed claims 48 and 49, holding that the PTAB has not actually addressed the additional limitations for these claims. This post will focus on the patentability of Claims 1-45, and specifically how the Federal Circuit affirmed the PTAB's application of the result-effective variable doctrine and reasonable expectation of success in order to arrive at a finding of obviousness of Claims 1-45 of U.S. Patent No. 9,492,599 ("the '559 patent").

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from